News

January 24, 2018January 24, 2018

Riemser Boosts Global Profile with New JA Therapies in Canada, Great Britain

News

Canadian government approval of Aristospan (triamcinolone hexacetonide) to treat juvenile arthritis reinforces the global expansion efforts of Germany’s Riemser Pharma, which recently acquired the U.K. distribution rights for Jylamvo (methotrexate). Jylamvo is ... Read more

January 19, 2018January 19, 2018

Study Identifies Juvenile Arthritis Patients Most Likely to Respond to NSAID Therapies

News

Juvenile arthritis patients younger than 8 whose disease is less advanced and who have lower levels of an inflammation marker are the likeliest to respond to a stand-alone, non-steroid anti-inflammatory ... Read more

January 17, 2018January 17, 2018

Standardized Treatments Needed for Pediatric Rheumatic Diseases, Experts Say

News

Considerable variability exists in how patients with pediatric rheumatic diseases are treated in clinical practice, making it hard to determine which therapies work best, a new review study says. This ... Read more

January 12, 2018January 12, 2018

Ontario Adds Erelzi to Public Health Plan for Juvenile Idiopathic Arthritis Treatment

News

Ontario has become the third Canadian province to add Erelzi (etanercept), a biosimilar therapy to Enbrel developed by Sandoz, to its public health plan for treatment of polyarticular juvenile idiopathic arthritis and ... Read more

January 10, 2018January 10, 2018

Adalimumab Improves Eye Inflammation of Children with Juvenile Arthritis, Phase 2/3 Trial Shows

News

Adalimumab improves the eye inflammation of children with early-onset juvenile idiopathic arthritis, a Phase 2/3 clinical trial shows. The study, published in the Annals of the Rheumatic Diseases, is titled “ADJUVITE: ... Read more

January 5, 2018January 5, 2018

Mental Disorders Are Common Among Children with Juvenile Arthritis, Other Chronic Diseases, Study Finds

News

More than half of children with diabetes, asthma, juvenile arthritis and other diseases have mental health problems, a Canadian study suggests. The research, “Mental disorder in children with physical conditions: ... Read more

January 3, 2018January 3, 2018

Treatment Escalation Decisions in JIA Best Supported by Simple Assessment Score, Study Suggests

News

A tool called the clinical Juvenile Arthritis Disease Activity Score (cJADAS) for measuring disease activity in patients with juvenile idiopathic arthritis (JIA) is more accurate in determining the need for ... Read more

December 22, 2017February 3, 2018

Girl’s Juvenile Arthritis and Water-retention Condition May Stem from Same Protein, Case Study Reports

News

Rhode Island Hospital doctors have reported what may be the first case of juvenile arthritis and a water-retention disorder appearing in the same youngster. The 6-year-old girl had systemic juvenile idiopathic ... Read more

December 20, 2017December 20, 2017

Golimumab Fails to Decrease Juvenile Arthritis Flare-ups Better Than Placebo, Trial Shows

News

Janssen Pharmaceuticals’ golimumab failed to meet its primary objective of reducing juvenile arthritis flare-ups better than a placebo, a Phase 3 clinical trial showed. Both the golimumab and placebo groups ... Read more

December 15, 2017December 15, 2017

JIA Patients in Remission with Subclinical Joint Inflammation Have Increased Flare Risk, Study Shows

News

The risk of flares increases in juvenile idiopathic arthritis (JIA) patients who are in remission, on medication, and have subclinical inflammation of the joints, a recent study found. Based on ... Read more